Synthetic Hybrid-Scale Fiber Matrix in the Trauma and Acute Care Surgical Practice

Luis Fernandez, MD, KHS, KCOEG, FACS, FASAS, FCCP, FCCM, FICS; Adam Shar, MD; Marc Matthews, MD, MS, FACS; Paul J. Kim, DPM; Christopher Thompson, MBA; Natalie Williams, MPAS, PA-C; Mandy Stutsman, RN

Disclosures

Wounds. 2021;33(9):237-244.

Conclusions

The successful clinical application of a synthetic hybrid-scale fiber matrix, as illustrated in these cases, suggests that its use may be warranted as part of the wound care continuum for the treatment of complex skin lesions (ie, refractory to existing therapies and interventions). Use of the synthetic matrix enables healing and provides economic benefits. This product may be a reasonable alternative to STSG, even in challenging cases involving a hostile local wound environment (eg, direct bile exposure) or in which the benefits of STSG may be outweighed by possible cutaneous complications (calciphylaxis).